dc.contributor.author | May, James | |
dc.contributor.author | Duncan, Colin | |
dc.contributor.author | Mol, Ben | |
dc.contributor.author | Bhattacharya, Siladitya | |
dc.contributor.author | Daniels, Jane | |
dc.contributor.author | Middleton, Lee | |
dc.contributor.author | Hewitt, Catherine | |
dc.contributor.author | Coomarasamy, Arri | |
dc.contributor.author | Jurkovic, Davor | |
dc.contributor.author | Bourne, Tom | |
dc.contributor.author | Bottomley, Cecilia | |
dc.contributor.author | Peace-Gadsby, Alexandra | |
dc.contributor.author | Doust, Ann | |
dc.contributor.author | Tong, Stephen | |
dc.contributor.author | Horne, Andrew W | |
dc.date.accessioned | 2019-05-30T09:50:07Z | |
dc.date.available | 2019-05-30T09:50:07Z | |
dc.date.issued | 2018-11-20 | |
dc.identifier | 144506647 | |
dc.identifier | 54d678a4-fef1-4a77-988f-da78dad8d059 | |
dc.identifier | 30458863 | |
dc.identifier | 85065349177 | |
dc.identifier.citation | May , J , Duncan , C , Mol , B , Bhattacharya , S , Daniels , J , Middleton , L , Hewitt , C , Coomarasamy , A , Jurkovic , D , Bourne , T , Bottomley , C , Peace-Gadsby , A , Doust , A , Tong , S & Horne , A W 2018 , ' A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3) : trial protocol ' , Trials , vol. 19 , 643 . https://doi.org/10.1186/s13063-018-3008-6 | en |
dc.identifier.issn | 1745-6215 | |
dc.identifier.other | PubMedCentral: PMC6247635 | |
dc.identifier.uri | http://hdl.handle.net/2164/12327 | |
dc.format.extent | 1023615 | |
dc.language.iso | eng | |
dc.relation.ispartof | Trials | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | Abortifacient Agents, Nonsteroidal/administration & dosage | en |
dc.subject | Adolescent | en |
dc.subject | Adult | en |
dc.subject | Clinical Trials, Phase III as Topic | en |
dc.subject | Double-Blind Method | en |
dc.subject | Drug Therapy, Combination | en |
dc.subject | ErbB Receptors/antagonists & inhibitors | en |
dc.subject | Female | en |
dc.subject | Gefitinib/administration & dosage | en |
dc.subject | Humans | en |
dc.subject | Methotrexate/administration & dosage | en |
dc.subject | Middle Aged | en |
dc.subject | Multicenter Studies as Topic | en |
dc.subject | Pregnancy | en |
dc.subject | Pregnancy, Tubal/diagnosis | en |
dc.subject | Protein Kinase Inhibitors/administration & dosage | en |
dc.subject | Randomized Controlled Trials as Topic | en |
dc.subject | Time Factors | en |
dc.subject | Treatment Outcome | en |
dc.subject | United Kingdom | en |
dc.subject | Young Adult | en |
dc.subject | R Medicine | en |
dc.subject | Supplementary Data | en |
dc.subject.lcc | R | en |
dc.title | A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3) : trial protocol | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Aberdeen Centre for Women’s Health Research | en |
dc.description.status | Peer reviewed | en |
dc.identifier.doi | 10.1186/s13063-018-3008-6 | |